Skip to main content
. 2022 Jun 28;13:913922. doi: 10.3389/fimmu.2022.913922

Figure 2.

Figure 2

Observed GMCs (points) and model estimates (solid line) with 95% confidence intervals (shaded area) for antibody titers across covariates. Note, results of the LMMs are presented as graphical representations, keeping stated covariates constant to visualise the effect of timing of maternal vaccination on cord antibody titers. (A) Model 1: GMC estimates for cord anti-PT titers at delivery by GAV across country with covariates: weight = mean birth weight, BA-EDD = 0 days. (B) Model 2: GMC estimates for cord anti-PT titers at delivery by interval between GAV and GAD across country with covariates: weight = mean birth weight. (C) Model 3: GMC estimates for cord anti-FHA titers at delivery by GAV across study groups with covariates: weight = mean birth weight, vaccine = Boostrix®. (D) Model 4: GMC estimates for cord anti-FHA titers at delivery by interval between GAV and GAD across study groups with covariates: weight = mean birth weight. (E) Model 5: GMC estimates for cord anti-PRN titers at delivery by GAV across country with covariates: weight = mean birth weight, age = mean age of mother at birth. (F) Model 6: GMC estimates for cord anti-PRN titers at delivery by interval between GAV and GAD across country with covariates: weight = mean birth weight, age = mean age of mother at birth, being term born. BA-EDD = number of days delivered before/after the due date, GAD = gestational age at delivery, GAV = gestational age at vaccination, GMC = geometric mean concentration, BE1 = Belgium 1, VN1 = Vietnam 1, TL1 = Thailand 1, BE2 = Belgium 2, BE3 = Belgium 3, PT = Pertussis Toxin, FHA = Filamentous Haemmaglutinin, PRN = Pertactin, LMMs = linear mixed models.